The pharmaceutical company MSD has signed collaboration agreement with the Stockholm County Council.
The parties have signed a letter of intent with the aim to achieve better quality of health care in Stockholm, especially regarding therapy areas where there is a growing need for improved treatment or diagnostics.
“In Sweden there is a unique health care environment with a great societal commitment in research, and the possibility to follow up treatment with world class records. A collaboration through the who value chain in health care there are great possibilites to optimize the care for Stockholm’s patients and also gather knowledge that can be helpful to many patients, not only in Sweden but also in other countries,” said Jacob Tellgren, CEO at MSD.
“The last years’ pharmaceutical development is formed by more expensive development costs without the equivalent increase in new products or therapeutical breakthrough. Health care has to better define its medical needs and collaborate with the pharmaceutical industry to achieve this through collaborative efforts. A collaboration makes it possible to streamline development costs and make them cheaper for the sake of better health. We hope that this will be the key to better health care for Stockholm’s patients,” said Jan Andersson, research director at Stockholm County Council.